These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 18038273)

  • 1. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC; Tong KH; To CH; Siu YP; Ma KM
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
    Kriel MH; Tobias JH; Creed TJ; Lockett M; Linehan J; Bell A; Przemioslo R; Smithson JE; Brooklyn TN; Fraser WD; Probert CS
    Osteoporos Int; 2010 Mar; 21(3):507-13. PubMed ID: 19484170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
    Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
    Sestak I; Singh S; Cuzick J; Blake GM; Patel R; Gossiel F; Coleman R; Dowsett M; Forbes JF; Howell A; Eastell R
    Lancet Oncol; 2014 Dec; 15(13):1460-1468. PubMed ID: 25456365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
    Reid DM; Adami S; Devogelaer JP; Chines AA
    Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
    Eastell R; Devogelaer JP; Peel NF; Chines AA; Bax DE; Sacco-Gibson N; Nagant de Deuxchaisnes C; Russell RG
    Osteoporos Int; 2000; 11(4):331-7. PubMed ID: 10928223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
    Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
    Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
    Hines SL; Mincey BA; Sloan JA; Thomas SP; Chottiner E; Loprinzi CL; Carlson MD; Atherton PJ; Salim M; Perez EA
    J Clin Oncol; 2009 Mar; 27(7):1047-53. PubMed ID: 19075260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
    McClung MR; Miller PD; Brown JP; Zanchetta J; Bolognese MA; Benhamou CL; Balske A; Burgio DE; Sarley J; McCullough LK; Recker RR
    Osteoporos Int; 2012 Jan; 23(1):267-76. PubMed ID: 21947137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
    Takei T; Itabashi M; Tsukada M; Sugiura H; Moriyama T; Kojima C; Shiohira S; Shimizu A; Karasawa K; Amemiya N; Kawanishi K; Ogawa T; Uchida K; Tsuchiya K; Nitta K
    Intern Med; 2010; 49(19):2065-70. PubMed ID: 20930431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Brufsky A; Lembersky BC; Bhattacharya R; Vujevich KT; Perera S; Sereika SM; Vogel VG
    J Clin Oncol; 2008 Jun; 26(16):2644-52. PubMed ID: 18427147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.